Beconase
NDC Package 16590-030-25

11-digit billing NDC: 16590003025 · Billing unit: GM

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Beconase is iNDICATIONS AND USAGEBECONASE AQ Nasal Spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis.Results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. Marketed by Stat Rx Usa Llc, this product is identified by NDC 16590-030 and is authorized under FDA application NDA019389.

Identification & Billing

NDC Package Code
16590-030-25
Package Description
180 SPRAY, SUSPENSION in 1 BOTTLE, PUMP
Product Code
11-Digit Billing Format
16590003025
Billing Unit
GM - Billing unit of "gram" is used when a product is measured by its weight.
RxNorm Crosswalk
  • RxCUI: 1797910 - beclomethasone dipropionate 42 MCG/ACTUAT Metered Dose Nasal Spray
  • RxCUI: 1797910 - beclomethasone dipropionate 0.042 MG/ACTUAT Metered Dose Nasal Spray
  • RxCUI: 1797917 - Beconase 42 MCG/ACTUAT Metered Dose Nasal Spray
  • RxCUI: 1797917 - beclomethasone dipropionate 0.042 MG/ACTUAT Metered Dose Nasal Spray [Beconase]
  • RxCUI: 1797917 - Beconase 0.042 MG/ACTUAT Metered Dose Nasal Spray

Clinical Specifications

Proprietary Name
Beconase AQ
Dosage Form
-
Usage Information
INDICATIONS AND USAGEBECONASE AQ Nasal Spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis.Results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. However, symptomatic relief may not occur in some patients for as long as 2 weeks. BECONASE AQ Nasal Spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. BECONASE AQ Nasal Spray should not be used in the presence of untreated localized infection involving the nasal mucosa.BECONASE AQ Nasal Spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal.Clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. Recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease.

Regulatory & Marketing

Labeler Name
Stat Rx Usa Llc
FDA Application #
NDA019389
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
10-01-1989
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 16590-030-25 identifies a specific commercial package of 180 spray, suspension in 1 bottle, pump of Beconase AQ, labeled by Stat Rx Usa Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Stat Rx Usa Llc on October 01, 1989. The current certification is valid through December 31, 2017.

How is this Stat Rx Usa Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 16590003025. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
16590-030-25
11-Digit CMS (5-4-2)
16590-0030-25

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.